Skip to main content

Drugs Made In America Acquisition Corp.

DMAAU
Exchange
Nasdaq
Industry
Blank Checks
SEC CIK
0002028614

No open-market purchases or sales by Drugs Made In America Acquisition Corp. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $122.3K in total; no superinvestor holds it.

Other share classesDMAADMAAR

Q1 2025 vs. Q4 2024

How the institutions holding Drugs Made In America Acquisition Corp. changed between Q4 2024 and Q1 2025.

All holders in Q1 2025All holders in Q4 2024

13F holders of DMAAU: Q4 2024 compared with Q1 2025
MeasureQ4 2024Q1 2025Change
Holders015+15
Shares03.29M+3.29M
Value$0$33.4M+$33.4M

New holders (15)

Institutions that held Drugs Made In America Acquisition Corp. at the end of Q1 2025 but not at the end of Q4 2024.

Institutions new to DMAAU in Q1 2025
InstitutionSharesValue% of portfolio
Heights Capital Management, Inc650,000$6.58M3.15%
Boothbay Fund Management, LLC603,750$6.14M0.22%
Westchester Capital Management, LLC500,000$5.06M0.29%
Rivernorth Capital Management, LLC420,498$4.28M0.23%
Context Capital Management, LLC250,000$2.54M0.10%
Schonfeld Strategic Advisors LLC234,831$2.39M0.02%
Bulldog Investors, LLP130,264$1.32M0.36%
Wolverine Asset Management LLC130,000$1.32M0.03%
Parallax Volatility Advisers, L.P.100,000$1.02M0.03%
Verition Fund Management LLC100,000$1.01M0.01%
Murchinson Ltd.90,000$915.3K0.16%
Tuttle Tactical Management40,000$406.8K1.79%
UBS Group AG18,278$185.9K0.00%
Citadel Advisors LLC15,753$159.4K0.00%
Clear Street LLC5,849$59.5K0.00%

Sold out (0)

Institutions that held Drugs Made In America Acquisition Corp. at the end of Q4 2024 and filed for Q1 2025 without it.

None.